How to Evaluate Preclinical and Clinical DILI

preview_player
Показать описание
In this webinar, InSphero CSO Prof. Armin Wolf will discuss how the research community gets “lost in translation” and share his strategy for bridging the divide between preclinical and clinical research to bring safe, effective drugs to market – and to patients in need of new therapeutics. Armin will introduce a “causality assay” framework for evaluating drug-induced liver injury (DILI) with novel 3D in vitro models and methodologies, and explain how multicellular 3D human liver spheroids can be used for investigating a broad range of experimental conditions using a variety of analytical methods, from liver enzyme markers and histological techniques to the latest ‘omics technologies. He'll also walk you through several examples of successful applications of causality assays for the deconvolution of major DILI mechanisms – and offer his vision for the future of 3D in vitro tools for translational liver toxicology – and beyond.
  1. InSphero
Рекомендации по теме
How to Evaluate 0:51:44

How to Evaluate Preclinical and Clinical DILI

Webinar — Critical 0:22:41

Webinar — Critical Sample Handling Processes for Preclinical and Clinical Studies

The Four Phases 0:03:54

The Four Phases of Clinical Trials | Diversity in Clinical Trials | AKF

#272 Evaluation of 0:09:15

#272 Evaluation of a novel preclinical model for bladder barrier evaluation using whole porcine...

Lost in translation: 0:21:58

Lost in translation: learning from preclinical data | Gerry Davies

Medicilon Preclinical Research-Pharmacology, 0:07:40

Medicilon Preclinical Research-Pharmacology, PK, and Safety Evaluation Services

Preclinical evaluation of 0:02:16

Preclinical evaluation of therapeutic cells using fluorescent nanodiamonds

preclinical safety program 0:04:34

preclinical safety program timeline

Multi-Organ Human on 0:57:04

Multi-Organ Human on a Chip Systems for Preclinical Efficacy and Toxicity Evaluations

Preclinical Development 0:02:36

Preclinical Development

CriPec Nanomedicines: Principles, 0:16:55

CriPec Nanomedicines: Principles, Preparation, Preclinical Evaluation and Early Clinical Translation

Drug discovery and 0:03:44

Drug discovery and preclinical evaluation phase

QUICK CHATS — 0:03:55

QUICK CHATS — Expertise in Preclinical Toxicology Studies

Quick Q&A with 0:01:28

Quick Q&A with AI Marvin｜Preclinical Evaluation of CAR-T/NK Cells Function

Towards best practice 0:11:54

Towards best practice in decision-enabling preclinical trials

Step Inside Altasciences' 0:00:29

Step Inside Altasciences' Preclinical Facility in Seattle, Washington

Short Clip - 0:06:27

Short Clip - Preclinical Pharmacokinetics (PK) and Pharmacodynamics (PD) Evaluation with Biocytogen

Stem Cell Clinical 0:47:00

Stem Cell Clinical Trials: Designing Preclinical Studies for First in Human Trials | Joy Cavagnaro

Image Analysis Enhances 0:35:52

Image Analysis Enhances Pathology Evaluation of Preclinical Studies, not Replaces it.

Medicilon's Preclinical Drug 0:00:28

Medicilon's Preclinical Drug Safety Evaluation Services

Drug Discovery and 0:20:27

Drug Discovery and Development | Detailed Explanation of Preclinical and Clinical Steps |

TALKING TOX WEBINAR 0:41:49

TALKING TOX WEBINAR - Best practices for the conduct of preclinical ototoxicity evaluation

Drug discovery and 0:34:54

Drug discovery and clinical evaluation of new drugs | Pharmacovigilance | L-11, U-2 | Pharmacology

Clinical relevance assessment 0:03:26

Clinical relevance assessment of animal preclinical research (RAA) tool: development and explanation